AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
parecoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| selective cyclo-oxygenase inhibitors | 2063 | 198470-84-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Parecoxib is a prodrug of valdecoxib. Valdecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range. Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 22, 2002 | EMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Negative pressure pulmonary oedema | 109.91 | 80.92 | 15 | 240 | 610 | 42620470 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Negative pressure pulmonary oedema | 110.35 | 58.96 | 15 | 550 | 684 | 110588050 |
| Anaphylactic reaction | 66.26 | 58.96 | 24 | 541 | 114276 | 110474458 |
| Neuromuscular block prolonged | 63.68 | 58.96 | 10 | 555 | 1237 | 110587497 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AH04 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Coxibs |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:50629 | cyclooxygenase 2 inhibitor |
Related Drugs by ATC class:
M01AH Coxibs 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute postoperative pain | indication | 107401000119105 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.39 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 8.30 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 3.85 | SCIENTIFIC LITERATURE | ||||
| Nuclear receptor subfamily 4 group A member 2 | Nuclear other | IC50 | 4.87 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03716 | KEGG_DRUG |
| 198470-85-8 | SECONDARY_CAS_RN |
| C0915142 | UMLSCUI |
| CHEBI:73038 | CHEBI |
| PXB | PDB_CHEM_ID |
| CHEMBL1206690 | ChEMBL_ID |
| CHEMBL296913 | ChEMBL_ID |
| DB08439 | DRUGBANK_ID |
| C409945 | MESH_SUPPLEMENTAL_RECORD_UI |
| 119828 | PUBCHEM_CID |
| 2895 | IUPHAR_LIGAND_ID |
| 7816 | INN_ID |
| 9TUW81Y3CE | UNII |
| 279950 | RXNORM |
| 009631 | NDDF |
| 009632 | NDDF |
| 395289008 | SNOMEDCT_US |
| 409135005 | SNOMEDCT_US |
| 734520005 | SNOMEDCT_US |
| 9TUW81Y3CE | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Parecoxib Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0048 | INJECTION, POWDER, FOR SOLUTION | 40 mg | INTRAVENOUS | Export only | 1 sections |